It’s a complex balance - ensuring both the health and safety of employees across operations and uninterrupted availability of medicines - as the coronavirus pandemic ravages countries large and small. The pharma industry in India, like elsewhere, is using a mix of efforts, ranging from the standard work from home advisories and putting digital technology to use to daily temperature checks at sites, to manage business continuity.
Coronavirus Actions: How Pharma In India Is Handling Safety, Business Continuity
Scrip contacted a cross section of pharma firms in India to get a sense of how they are handling the extraordinary work-operations-employee well-being situation amid the coronavirus outbreak. Work from home mandates, deploying digital tools wherever possible, cut-back in field activities and daily temperature checks at sites are some of the initiatives set in motion.

More from Business
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
More from Scrip
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
The company closed a $150m series C funding round shortly after opening the second part of its Phase I/II study of ATSN-201 and partnering with a Nippon Shinyaku on ATSN-101.
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.